Sickle Cell Disease Whole Blood

Sickle Cell Disease Whole Blood for Haematology and Genetic Research

Sanguine collects fresh Sickle Cell Disease Whole Blood from IRB-consented donors with a clinically confirmed sickle cell disease diagnosis, with same-day collection and shipment. Sickle cell disease is an inherited monogenic haemoglobinopathy caused by the HBB Glu6Val (HbS) variant: on deoxygenation, HbS polymerises, deforming red cells and producing vaso-occlusion, chronic haemolysis, and endothelial activation. Whole blood preserves intact red cells, leukocytes, and platelets together, which is essential for sickling, rheology, and haemolysis work.

Disease Biology and Why Whole Blood

• Defined molecular defect: a single HBB point mutation substituting valine for glutamic acid at position 6 of the beta-globin chain produces HbS.
• Polymerisation and sickling: deoxygenated HbS forms intracellular polymers, causing red cell rigidity, membrane damage, and dehydration — measurable only in intact cells, which whole blood preserves.
• Vaso-occlusion and chronic haemolysis: haemolysis releases free haemoglobin and arginase, depletes nitric oxide, and drives endothelial activation, contributing to pulmonary hypertension, stroke, nephropathy, and leg ulceration.
• Inflammation and adhesion: activated neutrophils, monocytes, platelets, and adhesion molecules participate in vaso-occlusive events, making paired cellular and plasma readouts valuable.
• Fetal haemoglobin (HbF) modulation is the central therapeutic axis; whole blood supports haemoglobin fractionation, F-cell measurement, and treatment-response studies.
• Genomic DNA for HBB genotyping and for genetic modifiers of severity (including BCL11A and alpha-thalassaemia co-inheritance) is recoverable from the same draw.

Donor Stratification Available

• Genotype: HbSS, HbSC, HbS/beta-thalassaemia, and other compound heterozygous states where available
• Treatment status: hydroxyurea, chronic transfusion, exchange transfusion, or treatment-naive
• Newer disease-modifying therapy exposure where available
• Clinical severity: vaso-occlusive crisis frequency, history of acute chest syndrome, stroke, or avascular necrosis
• Steady-state versus recent crisis collection
• Comorbid organ involvement: sickle nephropathy, pulmonary hypertension, retinopathy
• Paediatric and adult donors
• Matched healthy controls available

Product Features

• Fresh whole blood from clinically diagnosed sickle cell disease donors
• Custom anticoagulants and collection tubes available
• Same-day collection and shipment
• Research Use Only (RUO)
• IRB-approved protocols with documented electronic consent
• Custom volumes available on request

De-identified Donor Data

• Physician-confirmed diagnosis, including genotype (HbSS, HbSC, etc.) where available
• Demographics: age, sex assigned at birth, race/ethnicity
• Relevant medical and treatment history, including hydroxyurea and transfusion status
• Additional sickle cell disease-specific metadata available on request

Applications

• HBB gene variant analysis and haemoglobin polymerisation research
• Sickling assays, red cell deformability, and blood rheology studies
• Haemoglobin fractionation, HbF quantification, and F-cell measurement
• Vaso-occlusion, adhesion, and haemolysis biomarker studies
• Gene expression and transcriptomic analysis of circulating cells
• Gene therapy and gene editing research, including base editing and HbF induction strategies
• Hydroxyurea and disease-modifying therapy response research
• Genetic modifier discovery and severity prediction

Sickle Cell Disease vs Sickle Cell Trait

This product is the disease page: donors carry two abnormal beta-globin alleles (HbSS, HbSC, HbS/beta-thalassaemia) and have clinically manifest sickle cell disease. It should not be confused with sickle cell trait, the heterozygous carrier state (HbAS), which is typically asymptomatic and is not sickle cell disease. If you need carrier-state material, see our Sickle Cell Trait Whole Blood product.

Other Sickle Cell Disease Specimen Types

Sickle cell disease donor material is also available as Sickle Cell Disease Plasma, Sickle Cell Disease Serum, and Sickle Cell Disease PBMC.

Compliance and Quality Assurance

• IRB-approved protocols and electronic informed consent
• HIPAA-compliant donor data handling
• Documentation support available for regulatory review

Ordering & Customization

Sickle cell disease whole blood is available in standard and custom volumes. For pricing, international orders, or documentation requirements, email learnmore@sanguinebio.com. For the full specimen range, see our human whole blood collection.